Difference between revisions of "Cisplatin (Platinol)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information")
 
(28 intermediate revisions by 2 users not shown)
Line 2: Line 2:
 
Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.<ref name="insert">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de6302d5-85f0-4116-a709-57826c2c84fe Cisplatin (Platinol) package insert]</ref><ref>[[:File:Cisplatin.pdf | Cisplatin (Platinol) package insert (locally hosted backup)]]</ref>
 
Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.<ref name="insert">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de6302d5-85f0-4116-a709-57826c2c84fe Cisplatin (Platinol) package insert]</ref><ref>[[:File:Cisplatin.pdf | Cisplatin (Platinol) package insert (locally hosted backup)]]</ref>
 
<br>Route: IV, intracavitary (intraperitoneal)
 
<br>Route: IV, intracavitary (intraperitoneal)
−
<br>Extravasation: [[vesicant]] (concentration ≥0.5 mg/mL)/[[irritant]] (concentration <0.5 mg/mL)
+
<br>Extravasation: [[vesicant]] (concentration ≥0.5 mg/mL)/[[irritant]] (concentration less than 0.5 mg/mL)
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref>
 +
 
 +
==Diseases for which it is established ''(work in progress)''==
 +
*[[Bladder cancer]]
 +
*[[Malignant pleural mesothelioma]]
 +
*[[Nasopharyngeal carcinoma]]
 +
*Non-Hodgkin lymphoma
 +
**[[Mantle cell lymphoma]]
 +
**[[Peripheral T-cell lymphoma]]
 +
*[[Osteosarcoma]]
 +
*[[Ovarian cancer]]
 +
*[[Testicular cancer]]
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
Line 10: Line 21:
 
*[[Adrenocortical carcinoma]]
 
*[[Adrenocortical carcinoma]]
 
*[[Anal cancer]]
 
*[[Anal cancer]]
−
*[[Bladder cancer]]
 
 
*[[Breast cancer]]
 
*[[Breast cancer]]
 
*[[Carcinoma of unknown primary]]  
 
*[[Carcinoma of unknown primary]]  
Line 24: Line 34:
 
*[[Gastric cancer]]
 
*[[Gastric cancer]]
 
*[[Head and neck cancer]]
 
*[[Head and neck cancer]]
 +
**[[Oropharyngeal cancer, HPV-positive]]
 
*[[Hepatoblastoma]]
 
*[[Hepatoblastoma]]
−
*[[Hodgkin lymphoma]]
+
*[[Classical Hodgkin lymphoma]]
 
*[[Low-grade glioma]]
 
*[[Low-grade glioma]]
 +
**[[Low-grade glioma, pediatric]]
 
*[[Melanoma]]  
 
*[[Melanoma]]  
−
*[[Malignant pleural mesothelioma]]
 
 
*[[Medulloblastoma]]
 
*[[Medulloblastoma]]
 
*[[Multiple myeloma]]
 
*[[Multiple myeloma]]
−
*[[Nasopharyngeal carcinoma]]
 
 
*[[Neuroblastoma]]
 
*[[Neuroblastoma]]
 
*Non-Hodgkin lymphoma
 
*Non-Hodgkin lymphoma
Line 37: Line 47:
 
**[[Diffuse large B-cell lymphoma]]
 
**[[Diffuse large B-cell lymphoma]]
 
**[[Extranodal NK- and T-cell lymphoma, nasal type]]
 
**[[Extranodal NK- and T-cell lymphoma, nasal type]]
−
**[[Mantle cell lymphoma]]
+
**[[NK- and T-cell lymphoma]]
−
**[[Peripheral T-cell lymphoma]]
 
 
**[[Primary mediastinal B-cell lymphoma]]
 
**[[Primary mediastinal B-cell lymphoma]]
 
**[[Transformed lymphoma]]
 
**[[Transformed lymphoma]]
Line 44: Line 53:
 
**[[Non-small cell lung cancer, nonsquamous]]
 
**[[Non-small cell lung cancer, nonsquamous]]
 
**[[Non-small cell lung cancer, squamous]]
 
**[[Non-small cell lung cancer, squamous]]
−
*[[Osteosarcoma]]
 
−
*[[Ovarian cancer]]
 
 
*[[Pancreatic cancer]]
 
*[[Pancreatic cancer]]
 
*[[Penile cancer]]  
 
*[[Penile cancer]]  
 
*[[Small cell lung cancer]]
 
*[[Small cell lung cancer]]
−
*[[Testicular cancer]]
+
*[[Soft tissue sarcoma]]
 
*[[Thymoma]]
 
*[[Thymoma]]
 
*[[Upper tract urothelial carcinoma]]
 
*[[Upper tract urothelial carcinoma]]
 +
*[[Urothelial carcinoma]]
 
*[[Vulvar cancer]]
 
*[[Vulvar cancer]]
 
</div>
 
</div>
Line 57: Line 65:
 
==Patient drug information==
 
==Patient drug information==
 
*[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de6302d5-85f0-4116-a709-57826c2c84fe Cisplatin (Platinol) package insert]<ref name="insert"></ref>
 
*[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de6302d5-85f0-4116-a709-57826c2c84fe Cisplatin (Platinol) package insert]<ref name="insert"></ref>
−
*[https://chemocare.com/chemotherapy/drug-info/cisplatin.aspx Cisplatin (Platinol) patient drug information (Chemocare)]<ref>[https://chemocare.com/chemotherapy/drug-info/cisplatin.aspx Cisplatin (Platinol) patient drug information (Chemocare)]</ref>
+
*[https://chemocare.com/druginfo/cisplatin.aspx Cisplatin (Platinol) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/cisplatin.aspx Cisplatin (Platinol) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/cisplatin-patient-drug-information Cisplatin (Platinol) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cisplatin-patient-drug-information Cisplatin (Platinol) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/cisplatin-patient-drug-information Cisplatin (Platinol) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cisplatin-patient-drug-information Cisplatin (Platinol) patient drug information (UpToDate)]</ref>
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
* 12/19/1978: Initial FDA approval
+
*1978-12-19: Initial FDA approval
−
*9/2/2010: (earliest label available at Drugs@FDA) Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic [[testicular cancer|testicular tumors]] who have already received appropriate surgical and/or radiotherapeutic procedures.
+
*2010-09-02 (oldest label available at Drugs @ FDA): Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic [[testicular cancer|testicular tumors]] who have already received appropriate surgical and/or radiotherapeutic procedures. ''(No supporting studies are cited)''
−
*9/2/2010: (earliest label available at Drugs@FDA) Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic [[ovarian cancer|ovarian tumors]] who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of PLATINOL and cyclophosphamide. PLATINOL, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received PLATINOL therapy.
+
*2010-09-02 (oldest label available at Drugs @ FDA): Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic [[ovarian cancer|ovarian tumors]] who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of PLATINOL and cyclophosphamide. ''(Based on Wiernik et al. 1992a)''
−
*9/2/2010: (earliest label available at Drugs@FDA) Indicated as a single agent for patients with transitional cell [[bladder cancer]] which is no longer amenable to local treatments, such as surgery and/or radiotherapy.
+
*2010-09-02 (oldest label available at Drugs @ FDA): PLATINOL, as a single agent, is indicated as secondary therapy in patients with metastatic [[Ovarian cancer|ovarian tumors]] refractory to standard chemotherapy who have not previously received PLATINOL therapy. ''(Based on Wiernik et al. 1992a)''
 +
*2010-09-02 (oldest label available at Drugs @ FDA): Indicated as a single agent for patients with transitional cell [[bladder cancer]] which is no longer amenable to local treatments, such as surgery and/or radiotherapy. ''(No supporting studies are cited)''
 +
 
 +
==History of changes in EMA indication==
 +
*1978-12-19: EURD
 +
==History of changes in PMDA indication==
 +
*2012-02-22: New additional indication and a new dosage for the treatment of [[:Category:Biliary tract cancers|biliary tract cancer]].
  
 
==Also known as==
 
==Also known as==
−
*'''Code name:''' NSC 119875
+
*'''Code name:''' NSC-119875
 
*'''Generic names:''' CDDP, cis-diamminedichloroplatinum III, cis-platinum, cisplatinum, DACP, DDP
 
*'''Generic names:''' CDDP, cis-diamminedichloroplatinum III, cis-platinum, cisplatinum, DACP, DDP
 
*'''Brand names:'''
 
*'''Brand names:'''
Line 173: Line 187:
 
[[Category:Cervical cancer medications]]
 
[[Category:Cervical cancer medications]]
 
[[Category:Cholangiocarcinoma medications]]
 
[[Category:Cholangiocarcinoma medications]]
 +
[[Category:Cutaneous squamous cell carcinoma medications]]
 
[[Category:Diffuse large B-cell lymphoma medications]]
 
[[Category:Diffuse large B-cell lymphoma medications]]
 
[[Category:Endometrial cancer medications]]
 
[[Category:Endometrial cancer medications]]
Line 183: Line 198:
 
[[Category:Head and neck cancer medications]]
 
[[Category:Head and neck cancer medications]]
 
[[Category:Hepatoblastoma medications]]
 
[[Category:Hepatoblastoma medications]]
−
[[Category:Hodgkin lymphoma medications]]
+
[[Category:Classical Hodgkin lymphoma medications]]
 
[[Category:Low-grade glioma medications]]
 
[[Category:Low-grade glioma medications]]
 +
[[Category:Low-grade glioma, pediatric medications]]
 
[[Category:Mantle cell lymphoma medications]]
 
[[Category:Mantle cell lymphoma medications]]
 
[[Category:Medulloblastoma medications]]
 
[[Category:Medulloblastoma medications]]
Line 192: Line 208:
 
[[Category:Nasopharyngeal carcinoma medications]]
 
[[Category:Nasopharyngeal carcinoma medications]]
 
[[Category:Neuroblastoma medications]]
 
[[Category:Neuroblastoma medications]]
 +
[[Category:Neuroendocrine carcinoma medications]]
 +
[[Category:NK- and T-cell lymphoma medications]]
 
[[Category:Non-small cell lung cancer medications]]
 
[[Category:Non-small cell lung cancer medications]]
 
[[Category:Non-small cell lung cancer, nonsquamous medications]]
 
[[Category:Non-small cell lung cancer, nonsquamous medications]]
 
[[Category:Non-small cell lung cancer, squamous medications]]
 
[[Category:Non-small cell lung cancer, squamous medications]]
 +
[[Category:Oropharyngeal cancer medications]]
 
[[Category:Osteosarcoma medications]]  
 
[[Category:Osteosarcoma medications]]  
 
[[Category:Ovarian cancer medications]]
 
[[Category:Ovarian cancer medications]]
Line 202: Line 221:
 
[[Category:Primary mediastinal B-cell lymphoma medications]]  
 
[[Category:Primary mediastinal B-cell lymphoma medications]]  
 
[[Category:Small cell lung cancer medications]]
 
[[Category:Small cell lung cancer medications]]
−
[[Category:Cutaneous squamous cell carcinoma medications]]
+
[[Category:Soft tissue sarcoma medications]]
 
[[Category:Testicular cancer medications]]
 
[[Category:Testicular cancer medications]]
 
[[Category:Thymoma medications]]
 
[[Category:Thymoma medications]]
 
[[Category:Transformed lymphoma medications]]
 
[[Category:Transformed lymphoma medications]]
 
[[Category:Upper tract urothelial carcinoma medications]]
 
[[Category:Upper tract urothelial carcinoma medications]]
 +
[[Category:Urothelial carcinoma medications]]
 
[[Category:Vulvar cancer medications]]
 
[[Category:Vulvar cancer medications]]
  
 
[[Category:FDA approved in 1978]]
 
[[Category:FDA approved in 1978]]
 +
[[Category:EMA approved in 1978]]
 
[[Category:WHO Essential Cancer Medicine]]
 
[[Category:WHO Essential Cancer Medicine]]

Latest revision as of 01:04, 29 June 2024

General information

Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.[1][2]
Route: IV, intracavitary (intraperitoneal)
Extravasation: vesicant (concentration ≥0.5 mg/mL)/irritant (concentration less than 0.5 mg/mL)

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 1978-12-19: Initial FDA approval
  • 2010-09-02 (oldest label available at Drugs @ FDA): Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. (No supporting studies are cited)
  • 2010-09-02 (oldest label available at Drugs @ FDA): Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of PLATINOL and cyclophosphamide. (Based on Wiernik et al. 1992a)
  • 2010-09-02 (oldest label available at Drugs @ FDA): PLATINOL, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received PLATINOL therapy. (Based on Wiernik et al. 1992a)
  • 2010-09-02 (oldest label available at Drugs @ FDA): Indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. (No supporting studies are cited)

History of changes in EMA indication

  • 1978-12-19: EURD

History of changes in PMDA indication

Also known as

  • Code name: NSC-119875
  • Generic names: CDDP, cis-diamminedichloroplatinum III, cis-platinum, cisplatinum, DACP, DDP
  • Brand names:
Synonyms
Abiplatin Axiplat Biocisplatinum Bioplatino Blastolem Briplatin Brisplatin C-Platin
Ceplatin Ciplatan Ciplexal Cis-GRY Cismaplat Cispatin Cisplamerck Cisplan
Cisplasol Cisplatex Cisplatine Cisplatino Cisplatyl Cisteen Citoplatino Citosin
Cysplatyna Cytoplatin Docistin Elvecis Fauldcispla Ifapla Kemoplat Lederplatin
Metaplatin Neoplat Neoplatin Noveldexis Oncoplatin AQ Peyrone's Chloride Peyrone's Salt Placis
Plastistil Platamin Platamine Platiblastin Platicis Platidiam Platikem Platil
Platimit Platin Platinex Platinil Platino II Filaxis Platinol Platinox Platinoxan
Platiran Platistil Platistin Platistine Platosin Randa Romcis Sicatem
Sinplatin Sisplanil Tecnoplatin Tisplal Unistin

References

  1. ↑ 1.0 1.1 1.2 Cisplatin (Platinol) package insert
  2. ↑ Cisplatin (Platinol) package insert (locally hosted backup)
  3. ↑ Cisplatin (Platinol) patient drug information (Chemocare)
  4. ↑ Cisplatin (Platinol) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Cisplatin_(Platinol)&oldid=87344"